Pomalidomide plus Low-Dose Dexamethasone plus Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure

被引：0

作者：

Siegel, David S. ^{[1
,2
]}

Schiller, Gary J. ^{[3
]}

Samaras, Christy J. ^{[4
]}

Sebag, Michael ^{[5
]}

Berdeja, Jesus G. ^{[6
]}

Ganguly, Siddhartha ^{[7
]}

Matous, Jeffrey V. ^{[8
]}

Song, Kevin ^{[9
]}

Seet, Christopher S. ^{[10
]}

Talamo, Giampaolo ^{[11
]}

Acosta-Rivera, Mirelis ^{[12
]}

Bar, Michael ^{[13
]}

Quick, Donald P. ^{[14
]}

Anz, Bertrand ^{[15
]}

Fonseca, Gustavo ^{[16
]}

Reece, Donna ^{[17
]}

Agarwal, Amit ^{[18
]}

Chung, Weiyuan ^{[18
]}

Zafar, Faiza ^{[18
]}

Bahlis, Nizar ^{[19
]}

机构：

[1] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Myeloma Div, Hackensack, NJ USA

[2] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[3] UCLA, David Geffen Sch Med, Los Angeles, CA USA

[4] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[5] McGill Univ, Hlth Ctr, Montreal, PQ, Canada

[6] Sarah Cannon Res Inst, Nashville, TN USA

[7] Univ Kansas, Ctr Canc, Fairway, KS USA

[8] Colorado Blood Canc Inst, Denver, CO USA

[9] Vancouver Gen Hosp, Vancouver, BC, Canada

[10] UCLA, Med Ctr, Los Angeles, CA USA

[11] Penn State Hershey Canc Inst, Hershey, PA USA

[12] Fdn Invest, San Juan, PR USA

[13] Stamford Hosp, Stamford, CT USA

[14] Joe Arrington Canc Res Treatment Ctr, Lubbock, TX USA

[15] Tennessee Oncol, Chattanooga, TN USA

[16] Florida Canc Specialists, St Petersburg, FL USA

[17] Princess Margaret Canc Ctr, Toronto, ON, Canada

[18] Celgene Corp, Summit, NJ USA

[19] Univ Calgary, Calgary, AB, Canada

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111920

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3271

引用

页数：4

共 50 条

[31] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
Shinsuke Iida
Takaaki Chou
Shinichiro Okamoto
Hirokazu Nagai
Kiyohiko Hatake
Hirokazu Murakami
Toshiyuki Takagi
Kazuyuki Shimizu
Henry Lau
Kenichi Takeshita
Masaaki Takatoku
Tomomitsu Hotta
International Journal of Hematology, 2010, 92 : 118 - 126
[32] Lenalidomide plus dexamethasone demonstrates efficacy in the treatment of relapsed or refractory multiple myeloma
不详
FORMULARY, 2008, 43 (02) : 79 - 80
[33] Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma
Iida, Shinsuke
Chou, Takaaki
Okamoto, Shinichiro
Nagai, Hirokazu
Hatake, Kiyohiko
Murakami, Hirokazu
Takagi, Toshiyuki
Shimizu, Kazuyuki
Lau, Henry
Takeshita, Kenichi
Takatoku, Masaaki
Hotta, Tomomitsu
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (01) : 118 - 126
[34] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Bahlis, Nizar J.
Sutherland, Heather
White, Darrell
Sebag, Michael
Lentzsch, Suzanne
Kotb, Rami
Venner, Christopher P.
Gasparetto, Cristina
Del Col, Aldo
Neri, Paola
Reece, Donna
Kauffman, Michael
Shacham, Sharon
Unger, T. J.
Jeha, Jacqueline
Saint-Martin, Jean-Richard
Shah, Jatin
Chen, Christine
BLOOD, 2018, 132 (24) : 2546 - 2554
[35] Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey S. Y.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Mace, Sandrine
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth C.
BLOOD, 2022, 140
[36] Isatuximab plus pomalidomide/low-dose dexamethasone versus pomalidomide/low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (ICARIA-MM): final overall survival analysis
Richardson, Paul
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Malinge, Laure
Dubin, Franck
Morisse, Mony
Anderson, Kenneth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S32 - S32
[37] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
Palumbo, A.
Dimopoulos, M. A.
Richardson, P. G.
Siegel, D. S.
Cavo, M.
Corradini, P.
Weisel, K. C.
Delforge, M.
Chen, C.
Goldschmidt, H.
Jagannath, S.
Lockhorst, H. M.
Moreau, P.
Plesner, T.
Sternas, L.
Peluso, T.
Hong, K.
Herring, J.
Yu, X.
Zaki, M. H.
San Miguel, J.
HAEMATOLOGICA, 2016, 101 : 535 - 536
[38] Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
Jung, Seung-Hyun
Lee, Sung-Eun
Lee, Minho
Kim, So-Hee
Yim, Seon-Hee
Kim, Tae Woo
Min, Chang-Ki
Chung, Yeun-Jun
HAEMATOLOGICA, 2017, 102 (11) : E456 - E459
[39] Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment
Siegel, David S.
Weisel, Katja C.
Dimopoulos, Meletios A.
Baz, Rachid
Richardson, Paul G.
Delforge, Michel
Song, Kevin
San Miguel, Jesus
Moreau, Philippe
Yu, Xin
Hong, Kevin
Sternas, Lars
Zaki, Mohamed H.
Palumbo, Antonio
BLOOD, 2015, 126 (23)
[40] Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis
Moreau, Philippe
Dimopoulos, Meletios A.
Richardson, Paul G.
Siegel, David S.
Cavo, Michele
Corradini, Paolo
Weisel, Katja
Delforge, Michel
O'Gorman, Peter
Song, Kevin
Chen, Christine
Bahlis, Nizar
Oriol, Albert
Hansson, Markus
Kaiser, Martin
Anttila, Pekka
Raymakers, Reinier
Joao, Cristina
Cook, Gordon
Sternas, Lars
Biyukov, Tsvetan
Slaughter, Ana
Hong, Kevin
Herring, Jennifer
Yu, Xin
Zaki, Mohamed
San-Miguel, Jesus
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 99 (03) : 199 - 206

← 1 2 3 4 5 →